Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURETHAL Birch rush versus conventional up-dosing safety study
2013-000086-36Phase 4Completed
- Sponsor
- HAL Allergy Group
- Start
- Jun 2013
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Purethal Birch in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by HAL Allergy Group. Primary endpoint: Successful reaching of maintenance dose. Started Jun 2013; status: completed.
02
Drugs
Purethal Birch
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2013-000086-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000086-36.